NASDAQ: ELTX
Elicio Therapeutics Inc Stock

$7.52-0.46 (-5.76%)
Updated Feb 12, 2025
ELTX Price
$7.52
Fair Value Price
$1.18
Market Cap
$81.15M
52 Week Low
$3.34
52 Week High
$11.45
P/E
-1.08x
P/B
-4.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$46.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-3.02
Operating Cash Flow
-$38M
Beta
1.29
Next Earnings
Mar 27, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ELTX Overview

Angion is a clinical-stage biopharmaceutical company developing small molecule therapeutics to address fibrotic diseases and acute organ injuries. Its lead program is ANG-3070. Angion was founded in 1998 and headquartered in Uniondale, NY.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ELTX's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
C
Sentiment
F
Safety
D
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ELTX
Ranked
#462 of 557

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ELTX news, forecast changes, insider trades & much more!

ELTX News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ELTX ($7.52) is overvalued by 536.15% relative to our estimate of its Fair Value price of $1.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELTX ($7.52) is not significantly undervalued (536.15%) relative to our estimate of its Fair Value price of $1.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELTX due diligence checks available for Premium users.

Valuation

ELTX fair value

Fair Value of ELTX stock based on Discounted Cash Flow (DCF)

Price
$7.52
Fair Value
$1.18
Overvalued by
536.15%
ELTX ($7.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELTX ($7.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ELTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.08x
Industry
-144.01x
Market
37.75x

ELTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-4.27x
Industry
4.78x

ELTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$18.8M
Profit Margin
0%
ELTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$38.4M
Liabilities
$57.4M
Debt to equity
-3.02
ELTX's short-term assets ($30.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELTX's long-term liabilities ($48.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.3M
Investing
$0.0
Financing
$30.8M
ELTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ELTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ELTXD$81.15M-5.76%-1.08x-4.27x
AGENF$81.17M+7.79%-0.31x-0.28x
ANL$80.55M+7.11%2.35x1.51x
VERUD$80.51M+4.56%-1.96x2.49x
XFOR$82.03M+2.56%-6.01x1.38x

Elicio Therapeutics Stock FAQ

What is Elicio Therapeutics's quote symbol?

(NASDAQ: ELTX) Elicio Therapeutics trades on the NASDAQ under the ticker symbol ELTX. Elicio Therapeutics stock quotes can also be displayed as NASDAQ: ELTX.

If you're new to stock investing, here's how to buy Elicio Therapeutics stock.

What is the 52 week high and low for Elicio Therapeutics (NASDAQ: ELTX)?

(NASDAQ: ELTX) Elicio Therapeutics's 52-week high was $11.45, and its 52-week low was $3.34. It is currently -34.32% from its 52-week high and 125.01% from its 52-week low.

How much is Elicio Therapeutics stock worth today?

(NASDAQ: ELTX) Elicio Therapeutics currently has 10,791,326 outstanding shares. With Elicio Therapeutics stock trading at $7.52 per share, the total value of Elicio Therapeutics stock (market capitalization) is $81.15M.

Elicio Therapeutics stock was originally listed at a price of $170.20 in Feb 5, 2021. If you had invested in Elicio Therapeutics stock at $170.20, your return over the last 4 years would have been -95.58%, for an annualized return of -54.15% (not including any dividends or dividend reinvestments).

How much is Elicio Therapeutics's stock price per share?

(NASDAQ: ELTX) Elicio Therapeutics stock price per share is $7.52 today (as of Feb 12, 2025).

What is Elicio Therapeutics's Market Cap?

(NASDAQ: ELTX) Elicio Therapeutics's market cap is $81.15M, as of Feb 13, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Elicio Therapeutics's market cap is calculated by multiplying ELTX's current stock price of $7.52 by ELTX's total outstanding shares of 10,791,326.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.